1.35
+0.11(+8.87%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.27 |
| Day High | 1.4 |
| Day Low | 1.25 |
| 52-Week High | 2.27 |
| 52-Week Low | 0.4 |
| Volume | 277,427 |
| Average Volume | 296,041 |
| Market Cap | 73.19M |
| PE | -0.67 |
| EPS | -2.01 |
| Moving Average 50 Days | 1.37 |
| Moving Average 200 Days | 0.97 |
| Change | 0.11 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $45 as of January 11, 2026 at a share price of $1.35. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 5 years ago, it would be worth $15.7 as of January 11, 2026 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 4:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ l
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – - Third dose cohort
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
GlobeNewswire Inc.
Dec 07, 2025 1:00 PM GMT
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone - Dat